Completed2015-003503-39
Placebo-controlled Trial in Subjects at Ultra-high Risk for Psychosis With Omega-3 Fatty Acids in Europe
Interventional studyAges 13–20Multiple countriesSchizophrenia
Understand this study
Who was this study for?
Listed age limits: 13 years to 20 years.
- Listed locations
- Vienna and 13 more locationsSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateStarted: September 30, 2016
- Recruitment status
- Completed
- Enrollment listed in the registry
- 145
- Sponsor
- Rene Kahn
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug, Other
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- United Kingdom, Switzerland, Austria, ...
- Age range
- From 13 Years to 20 Years
- Official registry ID
- 2015-003503-39
- Official title
Show the full official title
Placebo-controlled Trial in Subjects at Ultra-high Risk for Psychosis With Omega-3 Fatty Acids in Europe
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Vienna, Austria · Tübingen, Germany · Petah Tikva, Israel
9 more locations
- Ramat Gan, Israel
- Rome, Italy
- Utrecht, Netherlands
- Bergen, Norway
- Barcelona, Spain
- Madrid, Spain
- Santander, Spain
- Zurich, Switzerland
- Edinburgh, United Kingdom
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Rene Kahn.
Did this study involve medication?
Yes. The study involved medication, including Omega-3 fatty acids.
Who was this study for?
Listed age limits: 13 years to 20 years.
